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Abstract Toll-like receptors (TLRs) play a crucial role in
the innate immune response and the subsequent induction of
adaptive immune responses against microbial infection or
tissue injury. Recent findings show that functional TLRs are
expressed not only on immune cells but also on cancer cells.
TLRs play an active role in carcinogenesis and tumor
progression during chronic inflammation that involves the
tumor microenvironment. Damage-associated molecular pat-
terns (DAMPs) derived from injured normal epithelial cells
and necrotic cancer cells appear to be present at significant
levels in the tumor microenvironment, and their stimulation
of specific TLRs can foster chronic inflammation. This
review discusses how carcinogenesis, cancer progression,
and site-specific metastasis are related to interactions
between cancer cells, immune cells, and DAMPs through
TLR activation in the tumor microenvironment.
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Abbreviations
APCs antigen-presenting cells
CCL2 chemokine C-C motif ligand 2
c-IAP-1 c-inhibitor of apoptosis protein-1
c-IAP-2 c-inhibitor of apoptosis protein-2
COX-2 cyclooxygenase-2
CpG-ODN cytosine-phosphate-guanine-
oligodeoxynucleotides
CXCL2 chemokine C-X-C motif ligand 2
CXCR4 CXC chemokine receptor-4
DAMPs damage-associated molecular patterns
EGFR epidermal growth factor receptor
HMGB1 high-mobility group box 1 protein
HSP heat shock proteins
ICAM-1 inter-cellular adhesion molecule 1
MAPK mitogen-associated protein kinase
MDSCs myeloid-derived suppressor cells
MyD88 myeloid differentiation factor 88
NF-κB nuclear factor kappa-light–chain-enhancer of
activated B cells
PAMPs pathogen-associated molecular patterns
TAMs tumor-associated macrophages
TGFβ transforming growth factor β
TLRs Toll-like receptors
VEGF vascular endothelial growth factor
XIAP X-linked inhibitor of apoptosis
Introduction
Recent studies have revealed that chronic inflammation
increases the risk of cancer development and progression
[1]. Inflammation is usually a host defense against invading
microbial pathogens, tissue destruction/injury or cancer. In
this setting, toll-like receptors (TLRs) play a crucial role in
the innate immune response and the subsequent induction
of adaptive immune responses [2]. TLRs are expressed not
only on immune cells but also on cancer cells. [3–12].
Activated TLR signals on cancer cells may promote cancer
progression, anti-apoptotic activity and resistance to host
immune responses [3–7, 13].
The tumor microenvironment, which includes cancer
cells, stressed normal cells, stromal tissue and extracellular
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e-mail: hoon@jwci.orgmatrix, has recently been implicated as a major factor for
progression and metastasis of cancer [14]. Stromal tissue
consists of fibroblasts, myofibroblasts, vascular and
lymphovascular endothelial cells, and infiltrating immune
cells such as antigen-presenting macrophages, dendritic
cells (DCs) and T-cells. Downregulation of the anti-tumor
activity of infiltrating immune cells has been suggested to
support cancer progression, angiogenesis and metastasis
[15, 16]. Recent studies show that activated TLRs
expressed on cancer cells can dampen the anti-tumor
functions of infiltrating immune cells, thereby altering the
inflammatory response in a manner that promotes cancer
progression [5, 6, 13].
This review will examine interactions between the tumor
microenvironment, TLRs expressed on immune and cancer
cells, and the pathogen-associated molecular patterns
(PAMPs) and damage-associated molecular patterns
(DAMPs) that are defined as TLR ligands. Understanding
how exogenous (PAMPs) or endogenous (DAMPs) danger
signals activate TLRs and oncogenesis in the setting of
chronic inflammation will facilitate development of more
effective therapeutic strategies against a wide variety of
cancers.
Toll-like Receptors and Ligands
TLRs are pattern recognition receptors for ligand molecules
derived from microbes or host cells; TLR-ligand binding
plays a key role in innate immunity and subsequent
acquired immunity against microbial infection or tissue
injury [17, 18]. TLRs are evolutionary conserved from
invertebrates to humans, and the TLR family has at least 13
members [19]. Eleven members (TLR1 to TLR11) have
been identified in humans so far. These are expressed by
different types of immune cells; they are located on the cell
surface or in the cell cytoplasm; and they recognize
different DAMPs and PAMPs. PAMPs are conserved
molecular products derived from pathogens that include
Gram-positive and Gram-negative bacteria, fungi and
viruses. DAMPs are endogenous molecules released from
injured or dying cells. Both DAMPs and PAMPs initiate
immune responses through TLR signals [20]. The list of
ligands for TLRs continues to increase, particularly with
recent additions of mammalian cell molecules (Table 1).
T L R 2a n dT L R 4h a v eak e yr o l ei nr e c o g n i t i o n
of various bacteria: TLR2 can recognize lipoprotein,
lipoteichoic acid and peptidoglycan molecules derived from
Gram-positive bacteria, whereas TLR4 is necessary for
recognizing lipopolysaccharide (LPS) from the Gram-
negative bacterial cell wall. Both of these TLRs also are
crucial for responses to DAMPs [17, 18]. TLR5 recognizes
bacterial flagellin. TLR11 recognizes profilin-like molecule
from Toxoplasma. TLR3, 7, 8 and 9 are expressed in the
cytoplasm and can recognize invading viruses [19]; TLR3
responds to double-strand RNA, whereas TLR7 and
TLR8 respond to single-strand RNA. TLR9 recognizes
CpG-ODN derived from bacteria and viruses. TLR
heterodimers such as TLR1/2 and TLR2/6 interact with
a wider range of ligands than monomeric TLRs. Akira et
al. [19] have reviewed TLR signaling pathways during
pathogen recognition; they describe in detail the induction
of immune reactions via extracellular and intracellular
pathways mediated by myeloid differentiation factor 88
(MyD88), nuclear factor kappa-light–chain-enhancer of
activated B cells (NF-κB), and mitogen-associated protein
kinase (MAPK).
Toll-like Receptors and Chronic Inflammation
TLRs are expressed not only by immune cells but also by
normal epithelial cells in the digestive system, normal
keratinocytes in skin, alveolar and bronchial epithelial cells,
and epithelial cells of the female reproductive tract. These
epithelial cells lining an organ are the first line of defense
against invasion of microorganisms, and TLRs expressed in
epithelial cells have a crucial role in regulation of
proliferation and apoptosis. Recent studies report abnor-
mally upregulated TLR signals in epithelial cells undergo-
Table 1 TLRs and ligands
TLR Ligand
DAMP PAMP
TLR1 Triacyl lipoproteins
TLR2 Heat shock proteins Peptidoglycan
HMGB1 Lipoprotein
Lipoteichoic acid
Zymosan
TLR3 self dsRNA viral dsRNA
TLR4 Heat shock proteins Heat shock proteins
Fibrinogen Lipopolysaccharides
Heparan sulfate RSV fusion protein
Fibronectin MMTV envelope proteins
Hyaluronic acid Paclitaxel
HMGB1
TLR5 Flagellin
TLR6 Lipoteichoic acid
Triacyl lipoproteins
Zymosan
TLR7/TLR8 self ssRNA viral ssRNA
TLR9 self DNA Bacterial and viral DNA
TLR10 Unkown Unkown
TLR11 Profilin
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21]. Chronic inflammation caused by autoimmune disease
or microbial infections is an important risk factor for
colorectal cancer (inflammatory bowel disease), gastric
cancer (Helicobacter pylori), cervical cancer (human
papilloma virus), liver cancer (hepatitis virus B and C),
and hematologic malignancies (cytomegalovirus and
Epstein-Barr virus). More than 15% of cancers worldwide
have a direct infectious origin [22].
Chronic inflammation appears to be immunologically
distinct from acute infection. The acute phase of infection is
characterized by CD8
+ T-cell priming and activation of NK
cells. CD8
+ effector T-cells have a central role in tumor-
associated antigen (TAA)-specific immunity and thus in
elimination of tumors; activated NK cells stimulate the
maturation of DCs and facilitate adaptive anti-tumor immu-
nity. The absence or reduction of these functions during
chronic inflammation may promote tumor tolerance [23],
carcinogenesis and evolution of the tumor microenvironment.
Chronic inflammation has been thought to induce malignant
transformation by activation of oncogenes, inhibition of
tumor suppressors, and induction of immunosuppression.
TLRs are also expressed by cancer cells (Table 2). TLRs
expressed on cancer cells can upregulate the NF-κBc a s c a d e
and produce anti-apoptotic proteins that contribute to
carcinogenesis and cancer cell proliferation. They also can
mediate cancer cell release of cytokines and chemokines that
can recruit immune cells to enhance immunity in the tumor
microenvironment. These optimized immune cells release
further proinflammatory cytokines, proangiogenic factors
and growth factors, which impair the anti-tumor function of
antigen-presenting cells (APCs) and effector T-cells.
Contribution of TLR Signals to Carcinogenesis
The high risk of gastric cancer in patients with H. pylori-
associated chronic gastritis illustrates the link between
chronic inflammation and development of cancer [1].
TLR2, 4, 5 and 9 are expressed by normal gastric epithelial
cells, and TLR4 signaling has a key role in regulating the
proliferation and apoptosis of these cells. However, over-
expression of TLR4 has been demonstrated in H. pylori-
infected gastric epithelial cells. TLR4, 5 and 9 are strongly
expressed not only by gastric cancer cells but also by
metaplastic and dysplastic gastric epithelial cells from
patients with H. pylori gastritis [9, 24]. Continuous
stimulation of these TLRs by the LPS component of H.
pylori might upregulate inflammatory factors such as
cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2)
through activation of NF-κB; upregulation eventually leads
to progressive carcinogenic changes in normal gastric
epithelial cells [25].
A possible link between chronic inflammation, TLR
expression and oncogenesis also can be found in colorectal
cancer. Nine TLRs (TLR1-9) are expressed in normal
epithelial cells of the colon; three of these TLRs (TLR2-4)
are elevated in most colorectal cancer cell lines. Elevated
expression seems to be regulated by commensal bacteria in
the intestinal lumen [26]. TLR4 reportedly is overexpressed
in colorectal cancer cells from patients with colitis and in
colorectal cancer cells from a murine model of colitis;
interestingly, colorectal neoplasia is reduced in TLR4-
deficient mice [4]. In the same study, activation of TLR4
by LPS led to neoplastic transformation via enhanced COX-
2 expression and increased epidermal growth factor receptor
(EGFR) signaling. This suggests that chronic inflammation
caused by commensal bacteria in the microenvironment may
be responsible for carcinogenesis through TLR signaling.
Epithelial cells of the female reproductive tract may
acquire carcinogenic changes through continuous TLR
stimulation by PAMPs. Four TLRs (TLR2-5) are expressed
by ovarian cancer cell lines [12]. TLR4 activation by LPS
promotes survival of ovarian cancer cells by inducing the
expression of antiapoptotic proteins, including X-linked
inhibitor of apoptosis (XIAP) and phosphorylated Akt [27].
Type of cancer TLR Reference citation
Gastric cancer TLR2,TLR4,TLR5,TLR9 [9, 24, 44]
Colorectal cancer TLR2,TLR3,TLR4,TLR5,TLR9 [4, 25, 26, 47, 69]
Ovarian cancer TLR2,TLR3,TLR4,TLR5 [12, 13]
Cervical cancer TLR3, TLR4, TLR5,TLR9 [8, 28, 70]
Lung cancer TLR2,TLR3,TLR4,TLR9 [6, 33, 71]
Prostate cancer TLR4,TLR9 [7, 29]
Melanoma TLR2,TLR3,TLR4 [5, 72]
Brain cancer TLR2,TLR4 [3, 73]
Breast cancer TLR2,TLR3,TLR4,TLR9 [6, 10, 30]
Hepatocellular carcinoma TLR2,TLR3,TLR4,TLR6,TLR9 [11, 70]
Laryngeal cancer TLR2,TLR3,TLR4 [74]
Table 2 TLR expression in
human cancer cells
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carcinogenesis [8, 28]. The expression of TLR5 and TLR9
is absent or weak in normal cervical squamous epithelial
cells but gradually increases during progression of low-
grade cervical intraepithelial neoplasia (CIN) to high-grade
CIN and then to invasive cervical squamous cell carcinoma.
Four TLRs (TLR2-4 and 9) are expressed in lung cancer
cell lines. Activation of TLR4 by LPS induces resistance of
lung cancer cells to TNFα or TRAIL-induced apoptosis
through NF-κB upregulation [6]. Various levels of TLR9
expression are observed in tumor specimens from patients
with prostate cancer [7, 29], breast cancer, astrocytoma and
glioblastoma [30]. Activation of TLR9 by CpG-ODN or
bacterial DNA increases cancer cell invasion.
We recently reported high expression of three TLRs
(TLR2-4) in human cutaneous melanoma. Our in vivo and
in vitro studies showed that other TLRs were expressed less
frequently or at lower levels. All three TLRs were
functionally active. Stimulation with ligands specific for
each TLR (zymosan for TLR2, polyIMP/polyCMP [PIC]
for TLR3, and LPS for TLR4), upregulated TLR expression
and activated the adaptor protein MyD88 and NF-κB. After
stimulation, TLRs induced several inflammatory cytokines
and chemokines, as discussed in the next section, and
melanoma cell migration increased [5]. These findings
strongly suggest that activation of TLRs by melanoma cells
can activate inflammatory-related molecules that would
govern the status of tumor microenvironment.
TLRs expressed in normal epithelial cells appear to
contribute to carcinogenesis through NF-κBu p r e g u l a t i o n
and subsequent production of antiapoptotic factors such as
Bcl-x, c-IAP-1 and c-IAP-2. By contrast, TLRs expressed in
cancer cells appear to promote tumor progression by facilitat-
ing cell survival and migration in a tumor microenvironment
characterized by chronic inflammation and PAMPs [31, 32].
Cytokines and Chemokines Activated Through TLR
Signals
In our study of the immune response to stimulation of specific
TLRs in melanoma cell lines [5], we demonstrated that
exposure of cells to ligands specific for TLR2-4 significantly
upregulated proinflammatory cytokines (TNFα, G-CSF,
IL-1a, and IL-6), proinflammatory chemokines (CCL2 and
CXCL2), an immunsuppressive cytokine (IL-10), and an
inflammatory factor (COX-2). Ligation of TLRs expressed in
cancer cells reportedly also increases TGFβ, IL-8, CXCR4,
ICAM-1 and VEGF [6, 12, 13, 33]. Almost all of these
cytokines and chemokines promote tumor progression, and
their presence characterizes the tumor microenvironment’s
active release of various factors that have multiple effects on
tumor cells, immune cells and normal cells.
TGFβ, VEGF, CCL22 and IL-10 can induce
CD4
+CD25
+Foxp3
+ regulatory T cells (Tregs) in the tumor
microenvironment and tumor-draining regional lymph
nodes of cancer patients [16, 34]. These Tregs secrete
additional IL-10 and TGFβ, which suppress anti-tumor
functions of non-Treg T cells. Elevated tumor levels of
Tregs are linked to poor prognosis in several cancers [35].
IL-10, an immunsuppressive cytokine, upregulates expres-
sion of alternatively activated myeloid cells (M2c) in
tumor-associated macrophages (TAMs). M2c cells release
angiogenic and lymphoangiogenic factors that promote
lymphatic metastasis of cancer cells [36]. Inflammatory
mediators IL-1b, IL-6 and PGE2 recruit myeloid-derived
suppressor cells (MDSCs) in the tumor microenvironment
[37]. MDSCs have recently been recognized as critical
mediators of cancer progression; they inhibit the anti-tumor
immune response by release of arginase, nitric oxide
synthase (NOS) and TGFβ [15, 38]. Additionally, mature
myeloid DCs induce a strong T helper 1 (Th1)—type
immune response and are considered potent inducers of
TAA-specific immunity. However, in several cancers the
dominant population of DCs in the tumor microenviron-
ment is not functionally mature DCs but dysfunctional
DCs. Differentiation and maturation of these myeloid DCs
are profoundly suppressed by factors present in the tumor
microenvironment, including VEGF, IL-6, IL-1, TGFβ,
COX-2 and PGE2 [23]. Cancer cells also induce CXCL12,
TNFα and IL-8. CXCL12 recruits plasmacytoid DCs that
express CXCR4, the receptor of CXCL12, into the tumor
microenvironment. These plasmacytoid DCs induce sig-
nificant IL-10 production by T cells and therefore act
as immunsuppressants. Moreover, CXCL12, TNFα and
IL-8 attract vascular DCs to the tumor microenvironment,
with a subsequent increase in tumor vascularization and
metastasis [39]. This extensive and complex interaction
between immune cytokines/chemokines and immune cells is
initiated by TLRs and is responsible for an immunsuppressive
response in the tumor microenvironment.
Cancer-associated fibroblasts (CAFs) are important
components of the tumor microenvironment, and they
are the main cellular component of the tumor stroma.
Unlike normal fibroblasts, CAFs are perpetually activated
[40]. Their origin is not well understood, but they appear
to be as important as immune cells in the tumor
microenvironment [41]. A recent study proposed that
TGFβ has a crucial role in activation of CAFs [42].
Activated CAFs promote the proliferation and progression
of cancer through the production of growth factors and
metalloproteinases. Therefore, a TLR-related increase in
TGFβ might lead to assembly and activation of CAFs in
the tumor microenvironment.
In summary, during cancer progression in the setting of
chronic inflammation, TLR ligands activate TLRs expressed
S208 Y. Sato et al.in cancer cells. Activated cancer cells release cytokines and
chemokines that are an important component of the tumor
microenvironment. Cytokine-activated infiltrating immune
cells subsequently can induce further cytokine release that
contributes to activation of CAFs and impairs the function of
APCs, effector T-cells and TAA-specific immunity; possibly
resulting tumor immunotolerance. The interplay and additive
effects of these events facilitate continuous activation of TLR
in cancer cells or adjacent normal epithelial cells, thereby
maintaining a hostile tumor microenvironment and promoting
tumor progression (Fig. 1).
TLRs and Tumor Angiogenesis
TLRs also seem to have an important role in tumor
angiogenesis, i.e., the formation of new capillary blood
vessels from existing vessels outside of the tumor. The
developing tumor depends on angiogenesis as a source of
more oxygen and nutrients for survival and growth.
Vascular endothelial growth factor (VEGF) is the main
factor involved in tumor angiogenesis and is part of the
aberrant molecular pattern associated with TLR signals.
VEGF is secreted by cancer cells directly and by immune
cells and CAFs. New vessels induced by VEGF are
abnormal: they are heterogeneous in distribution, irregular
in shape, and not organized into arterioles, venules and
capillaries. Their varied permeability leads to high
interstitial pressures and further hypoxia, which stimulates
additional VEGF production [43]. Hypoxia characterizes
solid tumors; it is a stress factor that might cause cells to
release DAMPs. These ligands activate TLR signals and
contribute to the aberrant molecular pattern in the tumor
microenvironment.
Fig. 1 TLR signals contribute to tumor progression in the tumor
microenvironment. PAMPs derived from microbes and DAMPs
derived from injured and necrotic cancer cells might activate TLRs
expressed on immune cells and on cancer cells. These activated cells
release cytokines and chemokines; the aberrant molecular pattern of
chemokines/cytokines might significantly affect the tumor microenvi-
ronment. Tregs: regulatory T cells, TAMs: tumor-associated macro-
phages, DCs: dendritic cells, CAFs: cancer-associated fibroblasts,
MDSCs: myeloid-derived suppressor cells
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investigated in H. pylori-associated gastric cancer [44].
This study reported that H. pylori-induced COX-2 expres-
sion and PGE2 release enhanced tumor angiogenesis via
TLR2 and 9. Another in vitro study found a direct
endothelial stimulatory role for LPS in initiating angiogen-
esis through activation of TLR signaling pathways [45].
HMGB1 has been recently recognized as a pro-angiogenic
factor [46]. HMGB1 upregulation induces the production
of VEGF and endothelial cell proliferation. Moreover,
HMGB1 acts on endothelial progenitor cells and hemato-
poietic stem cells to improve neovascularization of injured
or malignant tissue [46]. However, other studies show an
anti-angiogenic effect for TLRs. In a colorectal cancer
xenograft model, a TLR9 agonist reportedly interfered with
EGFR signaling and tumor angiogenesis and had a synergistic
effect with other EGFR inhibitors [47]. Imiquimod, a TLR7
agonist used as a topical immune-response modifier in
patients with skin cancers, can inhibit tumor angiogenesis
[48] by inducing anti-angiogenic cytokines such as IFNs, IL-
10 and IL-12; down-regulating pro-angiogenic factors such as
fibroblast growth factor β (FGFβ) and metalloproteinase-9
(MMP9); and promoting endothelial cell apoptosis [49].
Although the TLR contribution to tumor angiogenesis
remains unclear, interaction with ligands and TLRs seems
to have a major role in tumor angiogenesis and hypoxia in
tumor microenvironment, which supports tumor growth.
DAMPs Released from Injured or Necrotic Cancer Cells
Under normal conditions, scheduled cell death is regu-
lated by adenosine triphosphate (ATP) and related
apoptotic pathway factors; this regulation drives frag-
mentation of cellular macromolecules and the speedy
subsequent phagocytosis and clearance of apoptotic
debris. However, in cancerous conditions, cells dying
by non-apoptotic pathways, principally necrosis, release
DAMPs into the extracellular space. DAMPs are nuclear
or cytosolic proteins with defined intracellular functions
but different extracellular actions after cytolysis. DAMPs
released from injured or dying cells are recognized by
TLRs on immune cells; subsequent TLR signals disrupt
the anti-tumor immune response and lead to cancer
progression [18].
Candidate DAMPs include heat shock proteins (HSP 60,
70), ATP and uric acid, the S100 family of calcium
modulated proteins, nuclear protein high-mobility group
box 1 (HMGB1), and nucleic acids. HMGB1, a DNA
binding protein, is one of the best-characterized DAMP.
HMGB1 regulates intracellular transcription and mediates
extracellular proinflammatory processes. HMGB1 released
during unscheduled cell death activates an immune
response via TLR signals. Cell line studies show that
HMGB1 is strongly up-regulated in breast cancer, colon
cancer, melanoma, pancreatic cancer and prostate cancer;
upregulated HMGB1 activates TLR2 and TLR4 expressed
on immune cells and induces cancer progression and
metastasis [20].
We previously reported elevated expression of S100
proteins in melanoma cell lines relative to normal melano-
cyte lines. S100 proteins released by melanoma cells
stimulated melanoma cells as well as PBLs and acted as
an autocrine tumor growth factor [50]. S100A4 is respon-
sible for metastasis and is an indicator of poor prognosis for
patients with breast cancer [51]. However, although this
inflammatory protein is associated with metastatic cancer
cells, in the tumor microenvironment it is also expressed by
macrophages, lymphocytes and fibroblasts. Elevated inter-
stitial fluid levels of S100A4 in tumors [52] suggest that
stromal cells in the tumor microenvironment externalize
S100A4, which then activates TLR signals. Recent studies
reveal that S100A8 and S100A9 produced by primary
tumors can activate serum amyloid A (SAA) 3 in lung
tissue prior to pulmonary metastasis. SAA3 has a role in the
accumulation of myeloid cells and acts as a positive-
feedback regulator for secretion of S100 proteins. SAA3 is
a ligand for TLR4 in lung endothelial cells and macro-
phages. The activation of TLR4 facilitates migration of
cancer cells from the primary tumor to lung tissue by
creating a tumor microenvironment [53]. Blocking the
S100-TLR4 cascade therefore might be an effective
strategy for the prevention of pulmonary metastasis.
Nucleic Acid Fragments Act as DAMPs
During tumor expansion, nucleic acids released from
necrotic cancer cells or adjacent injured normal epithelial
cells act as DAMPs. Kariko et al. [54] demonstrated that
TLR3 expressed in DCs was activated by mRNA released
from necrotic cells; subsequent TLR signals upregulated
DC maturation, leading to IFN-α secretion. This upregulation
could be abolished by pretreatment of necrotic cells with
RNase. The mRNA released by cancer cells circulates in the
blood [55] and its serum levels have been correlated with
disease outcome [56]. In our studies, TLR3 expression was
upregulated (24.6–121.3% in mean value) in melanoma
cells incubated 12 h with purified total RNA from normal
PBL or allogeneic melanoma cells (Fig. 2), and TLR acti-
vation promoted melanoma cell migration [5]. Thus, RNA
derived from melanoma cells can act as a TLR3 ligand and
facilitate migration of melanoma cells, without support from
immune cells.
Likewise, absolute levels of circulating DNA in serum
and plasma appear to have diagnostic and prognostic
S210 Y. Sato et al.significance for various cancers [57]. The integrity of
circulating DNA, measured as the ratio of longer to shorter
DNA fragments, is higher in cancer patients than in normal
individuals [58]. Apoptotic cells release DNA fragments
that are usually 185 to 200 base pairs in length. Uniformly
truncated fragments of DNA (and RNA) are produced by a
programmed enzymatic cleavage process during apoptosis
[59]. As we and other groups have reported, methylation of
tumor suppression genes detected in circulating DNA is
associated with prognosis [60].
We speculate that the high rate of unscheduled cell death
in the tumor microenvironment elevates nucleic acid
DAMPs. Elevated levels of nucleic acid DAMPs and other
DAMPs might foster chronic inflammation, a hallmark of
the tumor microenvironment. Figure 3 shows how inter-
actions between TLRs and DAMPs could create and
maintain a self-perpetuating tumor microenvironment. In
this microenvironment, cancer cell death might stimulate
cancer progression if nucleic acid fragments released by the
dead tumor cells are transfected into normal cells, thereby
changing the normal cell’s properties. Normal cells in the
tumor microenvironment might also be transfected by
microRNA released from tumor cells, because these small
RNA molecules (20–22 base pairs) are easily taken up by
cells. Horizontal mediated transfection of microRNA and
mRNA in mammalian cells is an intriguing possibility but
has yet to be demonstrated in vivo. This phenomenon could
explain the expression of tumor-related proteins by normal
cells in the tumor microenvironment.
TLR-targeted Therapies
Because several TLRs can induce strong anti-tumor activity
by regulating the functions of immune cells that infiltrate
the tumor microenvironment, clinical trials are investigating
novel anticancer therapies based on TLR ligand delivery. A
successful example is imiquimod. This TLR7 agonist is
used extensively to treat actinic keratosis and basal cell
carcinoma, and it is being studied as an adjuvant therapy
for melanoma. A study of imiquimod 5% cream in 90
patients with basal cell carcinoma reported a 96% clearance
rate, and only two recurrences during application a mean
follow-up period of 36 months. Cutaneous side effects were
minimal; there were no systemic side effects [61]. Imiqui-
mod induces IFNα, IFNγ and IL-12, which activate APC
function and TAA-specific immunity, thereby correcting the
aberrant conditions of the tumor microenvironment [62]. As
mentioned above, imiquimod’s ability to inhibit tumor
angiogenesis and cause tumor regression suggests a link
between TLR7 and tumor angiogenesis.
Another imidazoquinoline agonist for TLR7 is 852A {N-
[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl) butyl]
methanesulfonamide, 3M-001}. This systemically adminis-
tered agent has 40 times greater aqueous solubility than
imiquimod. It is under clinical investigation for chronic
lymphatic leukemia and other solid tumors [63, 64]. CpG-
ODN agonists for TLR9 directly induce activation and
maturation of DCs, enhance differentiation of B cells into
antibody-secreting plasma cells, and promote development
of anti-tumor T-cell responses [65]. In a murine model of
human ovarian cancer, intraperitoneal administration of
CpG-ODN produced a stronger anti-tumor effect than
intravenous administration [66]. Early clinical trials are
investigating the safety and efficacy of TLR9 agonists for
treatment of breast cancer, colorectal cancer, lung cancer,
melanoma, glioblastoma and some lymphomas and leuke-
mias [67]. Macrophage activating lipopeptide-2 (MALP2)
is a TLR2/6 agonist that has demonstrated encouraging
results for treatment of pancreatic cancer: intratumoral
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Fig. 2 TLR3 ligation and
subsequent TLR3 mRNA
expression in melanoma cells
incubated with purified total
RNA from normal donor PBLs
or allogeneic melanoma cells.
When ME7 and ME1 human
melanoma cells were incubated
12 h with total RNA from
normal PBL and ME5
melanoma cells, mean TLR3
mRNA expression increased
24.6–121.3% as compared with
expression in control cells
without total RNA
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significantly prolonged survival of patients with incom-
pletely resectable disease, from 9 to 17 months [68]. These
agents affect the tumor microenvironment and the tumor
cells directly and indirectly.
Another therapeutic approach is to target DAMPs,
especially HMGB1, in inflammatory diseases and cancers.
HMGB1-targeted therapies are grouped according to their
ability to sequester HMGB1, target extracellular HMGB1,
target receptors, or inhibit HMGB1 release [20]. Targeting
DAMPs may neutralize tumor supporting events occurring
in the tumor microenvironment.
However, not all TLR agonists and not all TLRs signaling
pathways lead to clinically relevant anti-tumor activity. As
described in this review, the complicated interactions
between cancer cells, immune cells, and PAMPs/DAMPs in
the tumor microenvironment can promote the progression
of cancer and support inappropriate immune enhancement
or anti-tumor immune tolerance through TLR signaling
pathways. TLR-targeted therapeutics may also directly
affect TLR-expressing tumor cells. Further investigation
and better understanding of the relationship between TLRs
and the tumor microenvironment are required to clarify
mechanisms of tumor progression/metastasis and develop
more effective therapeutic approaches to many human
cancers.
Conclusion
TLRs are expressed on many types of cancer cells, tumor
stromal cells and infiltrating immune cells. TLR activation
during inflammation and injury plays an active role in the
surrounding microenvironment. Similarly, in carcinogenesis
and tumor progression TLRs play an active role in the
tumor microenvironment. During chronic inflammation,
abnormal activation of TLRs in normal fibroblasts and
epithelial cells might facilitate neoplastic transformation
and carcinogenesis. Cancer cells activated by TLR signals
can release cytokines and chemokines that recruit and
optimize immune cells to release further cytokines and
chemokines. The result is an aberrant cytokine profile
associated with immune tolerance, cancer progression and
propagation of the tumor microenvironment. DAMPs
derived from injured normal epithelial cells and necrotic
cancer cells appear to be present at significant levels in the
tumor microenvironment, and their stimulation of specific
TLRs might foster chronic inflammation. This mechanism
is complex and thus far not well understood; however, it is
clear that carcinogenesis, cancer progression, and site-
specific metastasis are related to interactions between
cancer cells, immune cells, DAMPs and PAMPs through
TLR signals in the tumor microenvironment. Better
understanding of these signals and pathways will lead to
TLR activation
chronic inflammation
Maintain
tumor microenvironment
support role
DAMPs
Tumor Microenvironment Responses
PAMPs
Aberrant molecular pattern of 
cytokines/chemokines
Immunotolerance
induction
Cancer progression
Tumor angiogenesis
Fig. 3 During cancer growth
and unscheduled cell death,
DAMPs derived from necrotic
cancer cells might continuously
activate TLRs and create a
chronic inflammatory condition
as well as PAMPs. TLR
ligation activates NF-κB and
MAPK signaling, causing the
production of proinflammatory
cytokines and chemokines. The
resulting aberrant molecular
pattern of cytokines/chemokines
might have a crucial role in
immunotolerance, maintain
tumor microenvironment, tumor
angiogenesis that supports
tumor progression
S212 Y. Sato et al.development of novel therapeutic approaches to a wide
variety of cancers.
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